On September 29, 2025, Genmab announced its intent to acquire Merus NV for $97 per share in an all-cash deal valued at approximately $8 billion. This acquisition, which has received unanimous approval from both companies, aims to enhance Genmab’s late-stage oncology pipeline by integrating Merus’s promising asset, petosemtamab, currently in Phase 3 trials. The deal is expected to close in early Q1 2026, providing liquidity to Merus shareholders and marking a significant move in Genmab’s transition to a wholly owned asset model. Investors should watch for regulatory updates and trial data pertinent to Merus’s pipeline as the acquisition progresses.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.ad-hoc-news.de/boerse/ueberblick/merus-nv-stock-genmab-acquisition-deal-at-97-per-share-reshapes-biotech/68998818
